𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Which factors influence therapeutic decisions in Parkinson's disease?

✍ Scribed by H. Baas; G. Fuchs; I. Gemende; R. Hueber; L. Lachenmayer; E. Schneider; B. Schoenberger; M. Werner

Publisher
Springer
Year
2002
Tongue
English
Weight
150 KB
Volume
249
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Milestones in Parkinson's disease therap
Milestones in Parkinson's disease therapeutics
✍ Olivier Rascol; Andres Lozano; Matthew Stern; Werner Poewe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

## Abstract In the mid‐1980s, the treatment of Parkinson's disease was quite exclusively centered on dopatherapy and was focusing on dopamine systems and motor symptoms. A few dopamine agonists and a monoamine oxidase B inhibitor (selegiline) were used as adjuncts in advanced Parkinson's disease. I

Inositol is not therapeutic in Parkinson
Inositol is not therapeutic in Parkinson's Disease
✍ Alex Mishori; Joseph Levine; Esther Kahana; R. H. Belmaker 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

Inositol 12 g per day was added to ongoing anti-Parkinson therapy in a controlled randomized cross-over design in nine patients. No therapeutic eect was found.